Gene-sex interactions in schizophrenia: Focus on dopamine neurotransmission

Frontiers in Behavioral Neuroscience

Volumn 8, Issue MAR, 2014, Pages

  Godar, Sean C ^a   Bortolato, Marco ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Catecholamine O methyltransferase (COMT); Dopamine; Gene sex interactions; Monoamine oxidase (MAO); Schizophrenia; Sex hormones

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); CATECHOL METHYLTRANSFERASE; DOPAMINE; ESTROGEN;

DOPAMINE GENE; DOPAMINE METABOLISM; DOPAMINERGIC TRANSMISSION; GENE INTERACTION; GENE SEX INTERACTION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HORMONE ACTION; HUMAN; NEUROPATHOLOGY; NONHUMAN; ONSET AGE; PROGNOSIS; REVIEW; SCHIZOPHRENIA; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84897007529     PISSN: 16625153     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnbeh.2014.00071     Document Type: Review

References (253)

1. Akhondzadeh, S., Nejatisafa, A. A., Amini, H., Mohammadi, M. R., Larijani, B., Kashani, L., et al. (2003). Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 1007-1012. doi: 10.1016/S0278-5846(03)00161-1
2. Akhondzadeh, S., Rezaei, F., Larijani, B., Nejatisafa, A. A., Kashani, L., and Abbasi, S. H. (2006). Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. Schizophr. Res. 84, 405-410. doi: 10.1016/j.schres.2006.02.008
3. Aksenova, M. G., Shestakova Iu, N., Abramova, L. I., Frolova, L. P., Shemiakina, T. K., Lezheiko, T. V., et al. (2004). [D3 dopamine receptor gene Ser9Gly polymorphism in Russian patients with schizophrenia]. Zh. Nevrol. Psikhiatr. Im. S S Korsakova 104, 57-61.
4. Allen, P., Luigjes, J., Howes, O. D., Egerton, A., Hirao, K., Valli, I., et al. (2012). Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals. Schizophr. Bull. 38, 1268-1276. doi: 10.1093/schbul/sbr194
5. Alvarez, S., Mas, S., Gasso, P., Bernardo, M., Parellada, E., and Lafuente, A. (2010). Lack of association between schizophrenia and polymorphisms in dopamine metabolism and transport genes. Fundam. Clin. Pharmacol. 24, 741-747. doi: 10.1111/j.1472-8206.2009.00807.x
6. Amstadter, A. B., Macpherson, L., Wang, F., Banducci, A. N., Reynolds, E. K., Potenza, M. N., et al. (2012). The relationship between risk-taking propensity and the COMT Val(158)Met polymorphism among early adolescents as a function of sex. J. Psychiatr. Res. 46, 940-945. doi: 10.1016/j.jpsychires.2012.04.010
7. Andersen, S. L. (2003). Trajectories of brain development: point of vulnerability or window of opportunity?Neurosci. Biobehav. Rev. 27, 3-18. doi: 10.1016/S0149-7634(03)00005-8
8. Anderson, L. I., Leipheimer, R. E., and Dluzen, D. E. (2005). Effects of neonatal and prepubertal hormonal manipulations upon estrogen neuroprotection of the nigrostriatal dopaminergic system within female and male mice. Neuroscience 130, 369-382. doi: 10.1016/j.neuroscience.2004.09.033
9. Angermeyer, M. C., and Kuhn, L. (1988). Gender differences in age at onset of schizophrenia. An overview. Eur. Arch. Psychiatr. Neurol. Sci. 237, 351-364. doi: 10.1007/BF00380979
10. Arime, Y., Kasahara, Y., Hall, F. S., Uhl, G. R., and Sora, I. (2012). Cortico-subcortical neuromodulation involved in the amelioration of prepulse inhibition deficits in dopamine transporter knockout mice. Neuropsychopharmacology 37, 2522-2530. doi: 10.1038/npp.2012.114
11. Asherson, P., Mant, R., Holmans, P., Williams, J., Cardno, A., Murphy, K., et al. (1996). Linkage, association and mutational analysis of the dopamine D3 receptor gene in schizophrenia. Mol. Psychiatry 1, 125-132.
12. Babovic, D., O'Tuathaigh, C. M., O'Connor, A. M., O'Sullivan, G. J., Tighe, O., Croke, D. T., et al. (2008). Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase. Neuroscience 155, 1021-1029. doi: 10.1016/j.neuroscience.2008.07.006
13. Balciuniene, J., Emilsson, L., Oreland, L., Pettersson, U., and Jazin, E. (2002). Investigation of the functional effect of monoamine oxidase polymorphisms in human brain. Hum. Genet. 110, 1-7. doi: 10.1007/s00439-001-0652-8
14. Bale, T. L. (2011). Sex differences in prenatal epigenetic programming of stress pathways. Stress 14, 348-356. doi: 10.3109/10253890.2011.586447
15. Ball, P., and Knuppen, R. (1980). Catecholoestrogens (2-and 4-hydroxyoestrogens): chemistry, biogenesis, metabolism, occurrence and physiological significance. Acta Endocrinol. Suppl. (Copenh). 232, 1-127.
16. Barnett, J. H., Heron, J., Goldman, D., Jones, P. B., and Xu, K. (2009). Effects of catechol-O-methyltransferase on normal variation in the cognitive function of children. Am. J. Psychiatry 166, 909-916. doi: 10.1176/appi.ajp.2009.08081251
17. Barnett, J. H., Jones, P. B., Robbins, T. W., and Müller, U. (2007). Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls. Mol. Psychiatry 12, 502-509. doi: 10.1038/sj.mp.4001973
18. Bay-Richter, C., O'Tuathaigh, C. M., O'Sullivan, G., Heery, D. M., Waddington, J. L., and Moran, P. M. (2009). Enhanced latent inhibition in dopamine receptor-deficient mice is sex-specific for the D1 but not D2 receptor subtype: implications for antipsychotic drug action. Int. J. Neuropsychopharmacol. 12, 403-414. doi: 10.1017/S1461145708009656
19. Benes, F. M., and Berretta, S. (2001). GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25, 1-27. doi: 10.1016/S0893-133X(01)00225-1
20. Bergemann, N., Parzer, P., Runnebaum, B., Resch, F., and Mundt, C. (2007). Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol. Med. 37, 1427-1436. doi: 10.1017/S0033291707000578
21. Bergen, S. E., Fanous, A. H., Walsh, D., O'neill, F. A., and Kendler, K. S. (2009). Polymorphisms in SLC6A4, PAH, GABRB3, and MAOB and modification of psychotic disorder features. Schizophr. Res. 109, 94-97. doi: 10.1016/j.schres.2009.02.009
22. Bertocci, B., Miggiano, V., Da Prada, M., Dembic, Z., Lahm, H. W., and Malherbe, P. (1991). Human catechol-O-methyltransferase: cloning and expression of the membrane-associated form. Proc. Natl. Acad. Sci. U.S.A. 88, 1416-1420. doi: 10.1073/pnas.88.4.1416
23. Bhakta, S. G., Zhang, J. P., and Malhotra, A. K. (2012). The COMT Met158 allele and violence in schizophrenia: a meta-analysis. Schizophr. Res. 140, 192-197. doi: 10.1016/j.schres.2012.06.026
24. Bilder, R. M., Volavka, J., Czobor, P., Malhotra, A. K., Kennedy, J. L., Ni, X., et al. (2002). Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol. Psychiatry 52, 701-707. doi: 10.1016/S0006-3223(02)01416-6
25. Bilder, R. M., Volavka, J., Lachman, H. M., and Grace, A. A. (2004). The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 29, 1943-1961. doi: 10.1038/sj.npp.1300542
26. Birgner, C., Kindlundh-Hogberg, A. M., Oreland, L., Alsio, J., Lindblom, J., Schioth, H. B., et al. (2008). Reduced activity of monoamine oxidase in the rat brain following repeated nandrolone decanoate administration. Brain Res. 1219, 103-110. doi: 10.1016/j.brainres.2008.05.014
27. Black, G. C., Chen, Z. Y., Craig, I. W., and Powell, J. F. (1991). Dinucleotide repeat polymorphism at the MAOA locus. Nucleic Acids Res. 19, 689. doi: 10.1093/nar/19.3.689-a
28. Blasi, G., Mattay, V. S., Bertolino, A., Elvevag, B., Callicott, J. H., Das, S., et al. (2005). Effect of catechol-O-methyltransferase val158met genotype on attentional control. J. Neurosci. 25, 5038-5045. doi: 10.1523/JNEUROSCI.0476-05.2005
29. Bortolato, M., Chen, K., and Shih, J. C. (2008b). Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv. Drug Deliv. Rev. 60, 1527-1533. doi: 10.1016/j.addr.2008.06.002
30. Bortolato, M., Frau, R., Orru, M., Bourov, Y., Marrosu, F., Mereu, G., et al. (2008). Antipsychotic-like properties of 5-alpha-reductase inhibitors. Neuropsychopharmacology 33, 3146-3156. doi: 10.1038/npp.2008.39
31. Boudikova, B., Szumlanski, C., Maidak, B., and Weinshilboum, R. (1990). Human liver catechol-O-methyltransferase pharmacogenetics. Clin. Pharmacol. Ther. 48, 381-389. doi: 10.1038/clpt.1990.166
32. Bouma, E. M., Riese, H., Doornbos, B., Ormel, J., and Oldehinkel, A. J. (2012). Genetically based reduced MAOA and COMT functioning is associated with the cortisol stress response: a replication study. Mol. Psychiatry 17, 119-121. doi: 10.1038/mp.2011.115
33. Bray, N. J., Buckland, P. R., Williams, N. M., Williams, H. J., Norton, N., Owen, M. J., et al. (2003). A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am. J. Hum. Genet. 73, 152-161. doi: 10.1086/376578
34. Breier, A. (1999). Cognitive deficit in schizophrenia and its neurochemical basis. Br. J. Psychiatry Suppl. 16-18.
35. Buckholtz, J. W., and Meyer-Lindenberg, A. (2008). MAOA and the neurogenetic architecture of human aggression. Trends Neurosci. 31, 120-129. doi: 10.1016/j.tins.2007.12.006
36. Burke, A. R., and Miczek, K. A. (2013). Stress in adolescence and drugs of abuse in rodent models: Role of dopamine, CRF, and HPA axis. Psychopharmacology (Berl). doi: 10.1007/s00213-013-3369-1. [Epub ahead of print].
37. Camarena, B., Fresan, A., Aguilar, A., Escamilla, R., Saracco, R., Palacios, J., et al. (2012). Monoamine oxidase a and B gene polymorphisms and negative and positive symptoms in schizophrenia. ISRN Psychiatry 2012:852949. doi: 10.5402/2012/852949
38. Carrera, N., Sanjuan, J., Molto, M. D., Carracedo, A., and Costas, J. (2009). Recent adaptive selection at MAOB and ancestral susceptibility to schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B, 369-374. doi: 10.1002/ajmg.b.30823
39. Cases, O., Seif, I., Grimsby, J., Gaspar, P., Chen, K., Pournin, S., et al. (1995). Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science 268, 1763-1766. doi: 10.1126/science.7792602
40. Caspi, A., McClay, J., Moffitt, T. E., Mill, J., Martin, J., Craig, I. W., et al. (2002). Role of genotype in the cycle of violence in maltreated children. Science 297, 851-854. doi: 10.1126/science.1072290
41. Caspi, A., Moffitt, T. E., Cannon, M., McClay, J., Murray, R., Harrington, H., et al. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol. Psychiatry 57, 1117-1127. doi: 10.1016/j.biopsych.2005.01.026
42. Chen, C. H., Lee, Y. R., Liu, M. Y., Wei, F. C., Koong, F. J., Hwu, H. G., et al. (1996). Identification of a BglI polymorphism of catechol-O-methyltransferase (COMT) gene, and association study with schizophrenia. Am. J. Med. Genet. 67, 556-559.
43. Chen, Y., Zhang, J., Zhang, L., Shen, Y., and Xu, Q. (2012). Effects of MAOA promoter methylation on susceptibility to paranoid schizophrenia. Hum. Genet. 131, 1081-1087. doi: 10.1007/s00439-011-1131-5
44. Cohen, R. Z., Seeman, M. V., Gotowiec, A., and Kopala, L. (1999). Earlier puberty as a predictor of later onset of schizophrenia in women. Am. J. Psychiatry 156, 1059-1064.
45. Collier, D. A., and Li, T. (2003). The genetics of schizophrenia: glutamate not dopamine? Eur. J. Pharmacol. 480, 177-184. doi: 10.1016/j.ejphar.2003.08.105
46. Collip, D., Van Winkel, R., Peerbooms, O., Lataster, T., Thewissen, V., Lardinois, M., et al. (2011). COMT Val158Met-stress interaction in psychosis: role of background psychosis risk. CNS Neurosci. Ther. 17, 612-619. doi: 10.1111/j.1755-5949.2010.00213.x
47. Coron, B., Campion, D., Thibaut, F., Dollfus, S., Preterre, P., Langlois, S., et al. (1996). Association study between schizophrenia and monoamine oxidase A and B DNA polymorphisms. Psychiatry Res. 62, 221-226. doi: 10.1016/0165-1781(96)02933-2
48. Costa-Mallen, P., Kelada, S. N., Costa, L. G., and Checkoway, H. (2005). Characterization of the in vitrotranscriptional activity of polymorphic alleles of the human monoamine oxidase-B gene. Neurosci. Lett. 383, 171-175. doi: 10.1016/j.neulet.2005.04.004
49. Creese, I., Burt, D. R., and Snyder, S. H. (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192, 481-483. doi: 10.1126/science.3854
50. Dahlin, A., Xia, L., Kong, W., Hevner, R., and Wang, J. (2007). Expression and immunolocalization of the plasma membrane monoamine transporter in the brain. Neuroscience 146, 1193-1211. doi: 10.1016/j.neuroscience.2007.01.072
51. Daniels, J. K., Williams, N. M., Williams, J., Jones, L. A., Cardno, A. G., Murphy, K. C., et al. (1996). No evidence for allelic association between schizophrenia and a polymorphism determining high or low catechol O-methyltransferase activity. Am. J. Psychiatry 153, 268-270.
52. Davis, K. L., Kahn, R. S., Ko, G., and Davidson, M. (1991). Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148, 1474-1486.
53. De Chaldee, M., Corbex, M., Campion, D., Jay, M., Samolyk, D., Petit, M., et al. (2001). No evidence for linkage between COMT and schizophrenia in a French population. Psychiatry Res. 102, 87-90. doi: 10.1016/S0165-1781(01)00237-2
54. Deckert, J., Catalano, M., Syagailo, Y. V., Bosi, M., Okladnova, O., Di Bella, D., et al. (1999). Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum. Mol. Genet. 8, 621-624. doi: 10.1093/hmg/8.4.621
55. Denney, R. M., Koch, H., and Craig, I. W. (1999). Association between monoamine oxidase A activity in human male skin fibroblasts and genotype of the MAOA promoter-associated variable number tandem repeat. Hum. Genet. 105, 542-551. doi: 10.1007/s004390051143
56. Devoto, P., Frau, R., Bini, V., Pillolla, G., Saba, P., Flore, G., et al. (2012). Inhibition of 5alpha-reductase in the nucleus accumbens counters sensorimotor gating deficits induced by dopaminergic activation. Psychoneuroendocrinology 37, 1630-1645. doi: 10.1016/j.psyneuen.2011.09.018
57. Diaz-Asper, C. M., Goldberg, T. E., Kolachana, B. S., Straub, R. E., Egan, M. F., and Weinberger, D. R. (2008). Genetic variation in catechol-O-methyltransferase: effects on working memory in schizophrenic patients, their siblings, and healthy controls. Biol. Psychiatry 63, 72-79. doi: 10.1016/j.biopsych.2007.03.031
58. Domschke, K., Baune, B. T., Havlik, L., Stuhrmann, A., Suslow, T., Kugel, H., et al. (2012). Catechol-O-methyltransferase gene variation: impact on amygdala response to aversive stimuli. Neuroimage 60, 2222-2229. doi: 10.1016/j.neuroimage.2012.02.039
59. Egan, M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., Straub, R. E., et al. (2001). Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 98, 6917-6922. doi: 10.1073/pnas.111134598
60. Egerton, A., Chaddock, C. A., Winton-Brown, T. T., Bloomfield, M. A., Bhattacharyya, S., Allen, P., et al. (2013). Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol. Psychiatry 74, 106-112. doi: 10.1016/j.biopsych.2012.11.017
61. Ehlis, A. C., Reif, A., Herrmann, M. J., Lesch, K. P., and Fallgatter, A. J. (2007). Impact of catechol-O-methyltransferase on prefrontal brain functioning in schizophrenia spectrum disorders. Neuropsychopharmacology 32, 162-170. doi: 10.1038/sj.npp.1301151
62. Engel, K., Zhou, M., and Wang, J. (2004). Identification and characterization of a novel monoamine transporter in the human brain. J. Biol. Chem. 279, 50042-50049. doi: 10.1074/jbc.M407913200
63. Estrada, G., Fatjo-Vilas, M., Munoz, M. J., Pulido, G., Minano, M. J., Toledo, E., et al. (2011). Cannabis use and age at onset of psychosis: further evidence of interaction with COMT Val158Met polymorphism. Acta Psychiatr. Scand. 123, 485-492. doi: 10.1111/j.1600-0447.2010.01665.x
64. Fink, G., Sumner, B. E., McQueen, J. K., Wilson, H., and Rosie, R. (1998). Sex steroid control of mood, mental state and memory. Clin. Exp. Pharmacol. Physiol. 25, 764-775. doi: 10.1111/j.1440-1681.1998.tb02151.x
65. Foley, D. L., Eaves, L. J., Wormley, B., Silberg, J. L., Maes, H. H., Kuhn, J., et al. (2004). Childhood adversity, monoamine oxidase a genotype, and risk for conduct disorder. Arch. Gen. Psychiatry 61, 738-744. doi: 10.1001/archpsyc.61.7.738
66. Fornai, F., Chen, K., Giorgi, F. S., Gesi, M., Alessandri, M. G., and Shih, J. C. (1999). Striatal dopamine metabolism in monoamine oxidase B-deficient mice: a brain dialysis study. J. Neurochem. 73, 2434-2440. doi: 10.1046/j.1471-4159.1999.0732434.x
67. Frau, R., Bini, V., Pes, R., Pillolla, G., Saba, P., Devoto, P., et al. (2014). Inhibition of 17alpha-hydroxylase/C17,20 lyase reduces gating deficits consequent to dopaminergic activation. Psychoneuroendocrinology 39, 204-213. doi: 10.1016/j.psyneuen.2013.09.014
68. Frau, R., Pillolla, G., Bini, V., Tambaro, S., Devoto, P., and Bortolato, M. (2013). Inhibition of 5alpha-reductase attenuates behavioral effects of D1-, but not D2-like receptor agonists in C57BL/6 mice. Psychoneuroendocrinology 38, 542-551. doi: 10.1016/j.psyneuen.2012.07.014
69. Fusar-Poli, P., Howes, O. D., Allen, P., Broome, M., Valli, I., Asselin, M. C., et al. (2011). Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol. Psychiatry 16, 67-75. doi: 10.1038/mp.2009.108
70. Gallinat, J., Bajbouj, M., Sander, T., Schlattmann, P., Xu, K., Ferro, E. F., et al. (2003). Association of the G1947A COMT (Val(108/158)Met) gene polymorphism with prefrontal P300 during information processing. Biol. Psychiatry 54, 40-48. doi: 10.1016/S0006-3223(02)01973-X
71. Garrick, N. A., and Murphy, D. L. (1980). Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain. Psychopharmacology (Berl). 72, 27-33. doi: 10.1007/BF00433804
72. Gasso, P., Bernardo, M., Mas, S., Crescenti, A., Garcia, C., Parellada, E., et al. (2008). Association of A/G polymorphism in intron 13 of the monoamine oxidase B gene with schizophrenia in a Spanish population. Neuropsychobiology 58, 65-70. doi: 10.1159/000159774
73. Godlewska, B. R., Olajossy-Hilkesberger, L., Limon, J., and Landowski, J. (2010). Ser9Gly polymorphism of the DRD3 gene is associated with worse premorbid social functioning and an earlier age of onset in female but not male schizophrenic patients. Psychiatry Res. 177, 266-267. doi: 10.1016/j.psychres.2010.02.012
74. Goel, N., and Bale, T. L. (2009). Examining the intersection of sex and stress in modelling neuropsychiatric disorders. J. Neuroendocrinol. 21, 415-420. doi: 10.1111/j.1365-2826.2009.01843.x
75. Gogos, J. A., Morgan, M., Luine, V., Santha, M., Ogawa, S., Pfaff, D., et al. (1998). Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc. Natl. Acad. Sci. U.S.A. 95, 9991-9996. doi: 10.1073/pnas.95.17.9991
76. Goldberg, T. E., Egan, M. F., Gscheidle, T., Coppola, R., Weickert, T., Kolachana, B. S., et al. (2003). Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch. Gen. Psychiatry 60, 889-896. doi: 10.1001/archpsyc.60.9.889
77. Goldman-Rakic, P. S., and Selemon, L. D. (1997). Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr. Bull. 23, 437-458. doi: 10.1093/schbul/23.3.437
78. Goncalves, V. F., Tiwari, A. K., De Luca, V., Kong, S. L., Zai, C., Tampakeras, M., et al. (2012). DRD4 VNTR polymorphism and age at onset of severe mental illnesses. Neurosci. Lett. 519, 9-13. doi: 10.1016/j.neulet.2012.04.027
79. Greenawalt, J. W., and Schnaitman, C. (1970). An appraisal of the use of monoamine oxidase as an enzyme marker for the outer membrane of rat liver mitochondria. J. Cell Biol. 46, 173-179. doi: 10.1083/jcb.46.1.173
80. Griffon, N., Crocq, M. A., Pilon, C., Martres, M. P., Mayerova, A., Uyanik, G., et al. (1996). Dopamine D3 receptor gene: organization, transcript variants, and polymorphism associated with schizophrenia. Am. J. Med. Genet. 67, 63-70. doi: 10.1002/(SICI)1096-8628(19960216)67:1%3C63::AID-AJMG11%3E3.0.CO;2-N
81. Gundlah, C., Lu, N. Z., and Bethea, C. L. (2002). Ovarian steroid regulation of monoamine oxidase-A and-B mRNAs in the macaque dorsal raphe and hypothalamic nuclei. Psychopharmacology (Berl). 160, 271-282. doi: 10.1007/s00213-001-0959-0
82. Häfner, H. (2002). Prevention and early intervention in schizophrenia: facts and visions. Seishin Shinkeigaku Zasshi 104, 1033-1054.
83. Häfner, H., Riecher-Rossler, A., An Der Heiden, W., Maurer, K., Fatkenheuer, B., and Loffler, W. (1993). Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia. Psychol. Med. 23, 925-940. doi: 10.1017/S0033291700026398
84. Han, D. H., Kee, B. S., Min, K. J., Lee, Y. S., Na, C., Park, D. B., et al. (2006). Effects of catechol-O-methyltransferase Val158Met polymorphism on the cognitive stability and aggression in the first-onset schizophrenic patients. Neuroreport 17, 95-99. doi: 10.1097/01.wnr.0000192740.38653.91
85. Han, D. H., Park, D. B., Na, C., Kee, B. S., and Lee, Y. S. (2004). Association of aggressive behavior in Korean male schizophrenic patients with polymorphisms in the serotonin transporter promoter and catecholamine-O-methyltransferase genes. Psychiatry Res. 129, 29-37. doi: 10.1016/j.psychres.2004.06.013
86. Harris, S. E., Wright, A. F., Hayward, C., Starr, J. M., Whalley, L. J., and Deary, I. J. (2005). The functional COMT polymorphism, Val 158 Met, is associated with logical memory and the personality trait intellect/imagination in a cohort of healthy 79 year olds. Neurosci. Lett. 385, 1-6. doi: 10.1016/j.neulet.2005.04.104
87. Harrison, P. J. (2000). Postmortem studies in schizophrenia. Dialogues Clin. Neurosci. 2, 349-357.
88. Henquet, C., Rosa, A., Krabbendam, L., Papiol, S., Fananas, L., Drukker, M., et al. (2006). An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 31, 2748-2757. doi: 10.1038/sj.npp.1301197
89. Herken, H., and Erdal, M. E. (2001). Catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association between symptomatology and prognosis. Psychiatr. Genet. 11, 105-109. doi: 10.1097/00041444-200106000-00009
90. Hinds, H. L., Hendriks, R. W., Craig, I. W., and Chen, Z. Y. (1992). Characterization of a highly polymorphic region near the first exon of the human MAOA gene containing a GT dinucleotide and a novel VNTR motif. Genomics 13, 896-897. doi: 10.1016/0888-7543(92)90181-Q
91. Hirvonen, M. M., Nagren, K., Rinne, J. O., Pesonen, U., Vahlberg, T., Hagelberg, N., et al. (2010). COMT Val158Met genotype does not alter cortical or striatal dopamine D2 receptor availability in vivo. Mol. Imaging Biol. 12, 192-197. doi: 10.1007/s11307-009-0257-5
92. Hoenicka, J., Garrido, E., Ponce, G., Rodriguez-Jimenez, R., Martinez, I., Rubio, G., et al. (2010). Sexually dimorphic interaction between the DRD1 and COMT genes in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B, 948-954. doi: 10.1002/ajmg.b.31065
93. Hoogendoorn, M. L., Bakker, S. C., Schnack, H. G., Selten, J. P., Otten, H. G., Verduijn, W., et al. (2005). No association between 12 dopaminergic genes and schizophrenia in a large Dutch sample. Am. J. Med. Genet. B Neuropsychiatr. Genet. 134B, 6-9. doi: 10.1002/ajmg.b.30147
94. Hotamisligil, G. S., and Breakefield, X. O. (1991). Human monoamine oxidase A gene determines levels of enzyme activity. Am. J. Hum. Genet. 49, 383-392.
95. Hovatta, I., Varilo, T., Suvisaari, J., Terwilliger, J. D., Ollikainen, V., Arajarvi, R., et al. (1999). A genomewide screen for schizophrenia genes in an isolated Finnish subpopulation, suggesting multiple susceptibility loci. Am. J. Hum. Genet. 65, 1114-1124. doi: 10.1086/302567
96. Howes, O. D., Bose, S. K., Turkheimer, F., Valli, I., Egerton, A., Valmaggia, L. R., et al. (2011). Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am. J. Psychiatry 168, 1311-1317. doi: 10.1176/appi.ajp.2011.11010160
97. Howes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., et al. (2012). The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch. Gen. Psychiatry 69, 776-786. doi: 10.1073/pnas.0511311103
98. Howes, O. D., and Kapur, S. (2009). The dopamine hypothesis of schizophreni: version III-the final common pathway. Schizophr. Bull. 35, 549-562. doi: 10.1093/schbul/sbp006
99. Howes, O. D., Williams, M., Ibrahim, K., Leung, G., Egerton, A., McGuire, P. K., et al. (2013). Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study. Brain136, 3242-3251. doi: 10.1093/brain/awt264
100. Huotari, M., Gainetdinov, R., and Männistö, P. T. (1999). Microdialysis studies on the action of tolcapone on pharmacologically-elevated extracellular dopamine levels in conscious rats. Pharmacol. Toxicol. 85, 233-238. doi: 10.1111/j.1600-0773.1999.tb02014.x
101. Hwang, R., Shinkai, T., De Luca, V., Ni, X., Potkin, S. G., Lieberman, J. A., et al. (2007). Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. J. Psychopharmacol. (Oxford) 21, 718-727. doi: 10.1177/0269881106072341
102. Hwu, H. G., Hong, C. J., Lee, Y. L., Lee, P. C., and Lee, S. F. (1998). Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia. Biol. Psychiatry 44, 483-487. doi: 10.1016/S0006-3223(98)00134-6
103. Ira, E., Zanoni, M., Ruggeri, M., Dazzan, P., and Tosato, S. (2013). COMT, neuropsychological function and brain structure in schizophrenia: a systematic review and neurobiological interpretation. J. Psychiatry Neurosci. 38, 366-380. doi: 10.1503/jpn.120178
104. Iwata, Y., Matsumoto, H., Minabe, Y., Osada, N., Nakamura, K., Sekizawa, T., et al. (2003). Early-onset schizophrenia and dopamine-related gene polymorphism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 116B, 23-26. doi: 10.1002/ajmg.b.10759
105. Jabbi, M., Korf, J., Kema, I. P., Hartman, C., Van Der Pompe, G., Minderaa, R. B., et al. (2007). Convergent genetic modulation of the endocrine stress response involves polymorphic variations of 5-HTT, COMT and MAOA. Mol. Psychiatry 12, 483-490. doi: 10.1038/sj.mp.4001975
106. Jablensky, A. (2003). "The epidemiological horizon, " in Schizophrenia, ed S. R. Hirsh, and D. R. Weinberger (Oxford: Blackwell Science), 203-231.
107. Jahng, J. W., Houpt, T. A., Wessel, T. C., Chen, K., Shih, J. C., and Joh, T. H. (1997). Localization of monoamine oxidase A and B mRNA in the rat brain by in situ hybridization. Synapse 25, 30-36.
108. Jonsson, E. G., Norton, N., Forslund, K., Mattila-Evenden, M., Rylander, G., Asberg, M., et al. (2003). Association between a promoter variant in the monoamine oxidase A gene and schizophrenia. Schizophr. Res. 61, 31-37. doi: 10.1016/S0920-9964(02)00224-4
109. Jonsson, E. G., Norton, N., Gustavsson, J. P., Oreland, L., Owen, M. J., and Sedvall, G. C. (2000). A promoter polymorphism in the monoamine oxidase A gene and its relationships to monoamine metabolite concentrations in CSF of healthy volunteers. J. Psychiatr. Res. 34, 239-244. doi: 10.1016/S0022-3956(00)00013-3
110. Kang, S. G., Park, Y. M., Choi, J. E., Lim, S. W., Lee, H. J., Lee, S. H., et al. (2010). Association study between antipsychotic-induced restless legs syndrome and polymorphisms of monoamine oxidase genes in schizophrenia. Hum. Psychopharmacol. 25, 397-403. doi: 10.1002/hup.1130
111. Karayiorgou, M., Gogos, J. A., Galke, B. L., Wolyniec, P. S., Nestadt, G., Antonarakis, S. E., et al. (1998). Identification of sequence variants and analysis of the role of the catechol-O-methyl-transferase gene in schizophrenia susceptibility. Biol. Psychiatry 43, 425-431. doi: 10.1016/S0006-3223(97)00202-3
112. Karoum, F., Chrapusta, S. J., Brinjak, R., Hitri, A., and Wyatt, R. J. (1994). Regional effects of amphetamine, cocaine, nomifensine and GBR 12909 on the dynamics of dopamine release and metabolism in the rat brain. Br. J. Pharmacol. 113, 1391-1399. doi: 10.1111/j.1476-5381.1994.tb17152.x
113. Kim, Y. R., Kim, J. H., Kim, S. J., Lee, D., and Min, S. K. (2008). Catechol-O-methyltransferase Val158Met polymorphism in relation to aggressive schizophrenia in a Korean population. Eur. Neuropsychopharmacol. 18, 820-825. doi: 10.1016/j.euroneuro.2008.07.009
114. Kim-Cohen, J., Caspi, A., Taylor, A., Williams, B., Newcombe, R., Craig, I. W., et al. (2006). MAOA, maltreatment, and gene-environment interaction predicting children's mental health: new evidence and a meta-analysis. Mol. Psychiatry 11, 903-913. doi: 10.1038/sj.mp.4001851
115. Ko, Y. H., Jung, S. W., Joe, S. H., Lee, C. H., Jung, H. G., Jung, I. K., et al. (2007). Association between serum testosterone levels and the severity of negative symptoms in male patients with chronic schizophrenia. Psychoneuroendocrinology 32, 385-391. doi: 10.1016/j.psyneuen.2007.02.002
116. Ko, Y. H., Lew, Y. M., Jung, S. W., Joe, S. H., Lee, C. H., Jung, H. G., et al. (2008). Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 28, 375-383. doi: 10.1097/JCP.0b013e31817d5912
117. Kotler, M., Barak, P., Cohen, H., Averbuch, I. E., Grinshpoon, A., Gritsenko, I., et al. (1999). Homicidal behavior in schizophrenia associated with a genetic polymorphism determining low catechol O-methyltransferase (COMT) activity. Am. J. Med. Genet. 88, 628-633. doi: 10.1002/(SICI)1096-8628(19991215)88:6<628::AID-AJMG10>3.0.CO;2-E
118. Kremer, I., Pinto, M., Murad, I., Muhaheed, M., Bannoura, I., Muller, D. J., et al. (2003). Family-based and case-control study of catechol-O-methyltransferase in schizophrenia among Palestinian Arabs. Am. J. Med. Genet. B Neuropsychiatr. Genet. 119B, 35-39. doi: 10.1002/ajmg.b.20008
119. Kuepper, R., Skinbjerg, M., and Abi-Dargham, A. (2012). The dopamine dysfunction in schizophrenia revisited: new insights into topography and course. Handb. Exp. Pharmacol. 1-26. doi: 10.1007/978-3-642-25761-2_1
120. Kulkarni, J., De Castella, A., Fitzgerald, P. B., Gurvich, C. T., Bailey, M., Bartholomeusz, C., et al. (2008). Estrogen in severe mental illness: a potential new treatment approach. Arch. Gen. Psychiatry 65, 955-960. doi: 10.1001/archpsyc.65.8.955
121. Kulkarni, J., De Castella, A., Smith, D., Taffe, J., Keks, N., and Copolov, D. (1996). A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr. Res. 20, 247-252. doi: 10.1016/0920-9964(96)82949-5
122. Kulkarni, J., Riedel, A., De Castella, A. R., Fitzgerald, P. B., Rolfe, T. J., Taffe, J., et al. (2002). A clinical trial of adjunctive oestrogen treatment in women with schizophrenia. Arch. Womens Ment. Health 5, 99-104. doi: 10.1007/s00737-002-0001-5
123. Lachman, H. M., Nolan, K. A., Mohr, P., Saito, T., and Volavka, J. (1998). Association between catechol O-methyltransferase genotype and violence in schizophrenia and schizoaffective disorder. Am. J. Psychiatry 155, 835-837.
124. Lachman, H. M., Papolos, D. F., Saito, T., Yu, Y. M., Szumlanski, C. L., and Weinshilboum, R. M. (1996). Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6, 243-250. doi: 10.1097/00008571-199606000-00007
125. Larsen, T. K., McGlashan, T. H., Johannessen, J. O., and Vibe-Hansen, L. (1996). First-episode schizophrenia: II. Premorbid patterns by gender. Schizophr. Bull. 22, 257-269. doi: 10.1093/schbul/22.2.257
126. Laruelle, M. (2003). "Dopamine transmission in the schizophrenic brain, " in Schizophrenia, ed S. R. Hirsh and D. R. Weinberger (Oxford: Blackwell Science), 365-387.
127. Lataster, J., Collip, D., Ceccarini, J., Hernaus, D., Haas, D., Booij, L., et al. (2014). Familial liability to psychosis is associated with attenuated dopamine stress signaling in ventromedial prefrontal cortex. Schizophr. Bull. 40, 66-77. doi: 10.1093/schbul/sbs187
128. Li, D., and He, L. (2008). Meta-study on association between the monoamine oxidase A gene (MAOA) and schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B, 174-178. doi: 10.1002/ajmg.b.30570
129. Li, W. J., Kou, C. G., Yu, Y., Sun, S., Zhang, X., Kosten, T. R., et al. (2012). Association of catechol-O-methyltransferase gene polymorphisms with schizophrenia and negative symptoms in a Chinese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 159B, 370-375. doi: 10.1002/ajmg.b.32038
130. Lin, S., Jiang, S., Wu, X., Qian, Y., Wang, D., Tang, G., et al. (2000). Association analysis between mood disorder and monoamine oxidase gene. Am. J. Med. Genet. 96, 12-14. doi: 10.1002/(SICI)1096-8628(20000207)96:1%3C12::AID-AJMG4%3E3.0.CO;2-S
131. Liou, Y. J., Tsai, S. J., Hong, C. J., Wang, Y. C., and Lai, I. C. (2001). Association analysis of a functional catechol-o-methyltransferase gene polymorphism in schizophrenic patients in Taiwan. Neuropsychobiology 43, 11-14. doi: 10.1159/000054858
132. Lu, B. Y., Martin, K. E., Edgar, J. C., Smith, A. K., Lewis, S. F., Escamilla, M. A., et al. (2007). Effect of catechol O-methyltransferase val(158)met polymorphism on the p50 gating endophenotype in schizophrenia. Biol. Psychiatry62, 822-825. doi: 10.1016/j.biopsych.2006.11.030
133. Luine, V. N., Khylchevskaya, R. I., and McEwen, B. S. (1975). Effect of gonadal steroids on activities of monoamine oxidase and choline acetylase in rat brain. Brain Res. 86, 293-306. doi: 10.1016/0006-8993(75)90704-0
134. Lundstrom, K., Salminen, M., Jalanko, A., Savolainen, R., and Ulmanen, I. (1991). Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol. 10, 181-189. doi: 10.1089/dna.1991.10.181
135. Luque, J. M., Bleuel, Z., Hendrickson, A., and Richards, J. G. (1996). Detection of MAO-A and MAO-B mRNAs in monkey brainstem by cross-hybridization with human oligonucleotide probes. Brain Res. Mol. Brain Res. 36, 357-360. doi: 10.1016/0169-328X(96)88407-5
136. Luque, J. M., Kwan, S. W., Abell, C. W., Da Prada, M., and Richards, J. G. (1995). Cellular expression of mRNAs encoding monoamine oxidases A and B in the rat central nervous system. J. Comp. Neurol. 363, 665-680. doi: 10.1002/cne.903630410
137. Ma, X., Sun, J., Yao, J., Wang, Q., Hu, X., Deng, W., et al. (2007). A quantitative association study between schizotypal traits and COMT, PRODH and BDNF genes in a healthy Chinese population. Psychiatry Res. 153, 7-15. doi: 10.1016/j.psychres.2007.02.003
138. Ma, Z. Q., Bondiolotti, G. P., Olasmaa, M., Violani, E., Patrone, C., Picotti, G. B., et al. (1993). Estrogen modulation of catecholamine synthesis and monoamine oxidase A activity in the human neuroblastoma cell line SK-ER3. J. Steroid Biochem. Mol. Biol. 47, 207-211. doi: 10.1016/0960-0760(93)90076-9
139. Malhotra, A. K., Kestler, L. J., Mazzanti, C., Bates, J. A., Goldberg, T., and Goldman, D. (2002). A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am. J. Psychiatry 159, 652-654. doi: 10.1176/appi.ajp.159.4.652
140. Männistö, P. T., and Kaakkola, S. (1999). Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 51, 593-628.
141. Männistö, P. T., Ulmanen, I., Lundstrom, K., Taskinen, J., Tenhunen, J., Tilgmann, C., et al. (1992). Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors. Prog. Drug Res. 39, 291-350.
142. Markham, J. A. (2012). Sex steroids and schizophrenia. Rev. Endocr. Metab. Disord. 13, 187-207. doi: 10.1007/s11154-011-9184-2
143. Matsumoto, C., Shinkai, T., Hori, H., Ohmori, O., and Nakamura, J. (2004). Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia. Psychiatry Res. 127, 1-7. doi: 10.1016/j.psychres.2004.03.011
144. Matsumoto, M., Weickert, C. S., Akil, M., Lipska, B. K., Hyde, T. M., Herman, M. M., et al. (2003). Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function. Neuroscience 116, 127-137. doi: 10.1016/S0306-4522(02)00556-0
145. McCarthy, M. M., Auger, A. P., Bale, T. L., De Vries, G. J., Dunn, G. A., Forger, N. G., et al. (2009). The epigenetics of sex differences in the brain. J. Neurosci. 29, 12815-12823. doi: 10.1523/JNEUROSCI.3331-09.2009
146. McCarthy, M. M., and Nugent, B. M. (2013). Epigenetic contributions to hormonally mediated sexual differentiation in the brain. J. Neuroendocrinol. doi: 10.1111/jne.12072. [Epub ahead of print].
147. Meltzer, H. Y., and Zureick, J. L. (1987). Relationship of auditory hallucinations and paranoia to platelet MAO activity in schizophrenics: sex and race interactions. Psychiatry Res. 22, 99-109. doi: 10.1016/0165-1781(87)90097-7
148. Meyer-Lindenberg, A., Buckholtz, J. W., Kolachana, B. R., Hariri, A., Pezawas, L., Blasi, G., et al. (2006). Neural mechanisms of genetic risk for impulsivity and violence in humans. Proc. Natl. Acad. Sci. U.S.A. 103, 6269-6274. doi: 10.1073/pnas.0511311103
149. Meyers, B., D'Agostino, A., Walker, J., and Kritzer, M. F. (2010). Gonadectomy and hormone replacement exert region-and enzyme isoform-specific effects on monoamine oxidase and catechol-O-methyltransferase activity in prefrontal cortex and neostriatum of adult male rats. Neuroscience 165, 850-862. doi: 10.1016/j.neuroscience.2009.11.013
150. Mihara, K., Kondo, T., Suzuki, A., Yasui, N., Nagashima, U., Ono, S., et al. (2000). Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene. Psychopharmacology 149, 246-250. doi: 10.1007/s002139900364
151. Mihara, K., Suzuki, A., Kondo, T., Yasui-Furukori, N., Ono, S., Otani, K., et al. (2001). Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol. Am. J. Med. Genet. 105, 271-274. doi: 10.1002/ajmg.1303
152. Min, J. A., Kim, J. J., Pae, C. U., Kim, K. H., Lee, C. U., Lee, C., et al. (2012). Association of estrogen receptor genes and schizophrenia: a preliminary study. Prog. Neuropsychopharmacol. Biol. Psychiatry 36, 1-4. doi: 10.1016/j.pnpbp.2011.09.012
153. Naudon, L., Dourmap, N., Leroux-Nicollet, I., and Costentin, J. (1992). Kainic acid lesion of the striatum increases dopamine release but reduces 3-methoxytyramine level. Brain Res. 572, 247-249. doi: 10.1016/0006-8993(92)90477-Q
154. Nolan, K. A., Bilder, R. M., Lachman, H. M., and Volavka, J. (2004). Catechol O-methyltransferase Val158Met polymorphism in schizophrenia: differential effects of Val and Met alleles on cognitive stability and flexibility. Am. J. Psychiatry 161, 359-361. doi: 10.1176/appi.ajp.161.2.359
155. Nolan, K. A., Volavka, J., Czobor, P., Cseh, A., Lachman, H., Saito, T., et al. (2000). Suicidal behavior in patients with schizophrenia is related to COMT polymorphism. Psychiatr. Genet. 10, 117-124. doi: 10.1097/00041444-200010030-00003
156. Norton, N., Kirov, G., Zammit, S., Jones, G., Jones, S., Owen, R., et al. (2002). Schizophrenia and functional polymorphisms in the MAOA and COMT genes: no evidence for association or epistasis. Am. J. Med. Genet. 114, 491-496. doi: 10.1002/ajmg.10517
157. O'Donnell, P. (2010). Adolescent maturation of cortical dopamine. Neurotox. Res. 18, 306-312. doi: 10.1007/s12640-010-9157-3
158. Ohnishi, T., Hashimoto, R., Mori, T., Nemoto, K., Moriguchi, Y., Iida, H., et al. (2006). The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia. Brain 129, 399-410. doi: 10.1093/brain/awh702
159. Opgen-Rhein, C., Neuhaus, A. H., Urbanek, C., Hahn, E., Sander, T., and Dettling, M. (2008). Executive attention in schizophrenic males and the impact of COMT Val108/158Met genotype on performance on the attention network test. Schizophr. Bull. 34, 1231-1239. doi: 10.1093/schbul/sbm155
160. Oreland, L., Nilsson, K., Damberg, M., and Hallman, J. (2007). Monoamine oxidases: activities, genotypes and the shaping of behaviour. J. Neural Transm. 114, 817-822. doi: 10.1007/s00702-007-0694-8
161. Ou, X. M., Chen, K., and Shih, J. C. (2006). Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1. J. Biol. Chem. 281, 21512-21525. doi: 10.1074/jbc.M600250200
162. Ozelius, L., Hsu, Y. P., Bruns, G., Powell, J. F., Chen, S., Weyler, W., et al. (1988). Human monoamine oxidase gene (MAOA): chromosome position (Xp21-p11) and DNA polymorphism. Genomics 3, 53-58. doi: 10.1016/0888-7543(88)90159-0
163. Paba, S., Frau, R., Godar, S. C., Devoto, P., Marrosu, F., and Bortolato, M. (2011). Steroid 5alpha-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders. Curr. Pharm. Des. 17, 151-167. doi: 10.2174/138161211795049589
164. Papaleo, F., Crawley, J. N., Song, J., Lipska, B. K., Pickel, J., Weinberger, D. R., et al. (2008). Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J. Neurosci. 28, 8709-8723. doi: 10.1523/JNEUROSCI.2077-08.2008
165. Papaleo, F., Erickson, L., Liu, G., Chen, J., and Weinberger, D. R. (2012). Effects of sex and COMT genotype on environmentally modulated cognitive control in mice. Proc. Natl. Acad. Sci. U.S.A. 109, 20160-20165. doi: 10.1073/pnas.1214397109
166. Parvizi, N., and Wuttke, W. (1983). Catecholestrogens affect catecholamine turnover rates in the anterior part of the mediobasal hypothalamus and medial preoptic area in the male and female castrated rat. Neuroendocrinology 36, 21-26. doi: 10.1159/000123523
167. Paspalas, C. D., and Goldman-Rakic, P. S. (2004). Microdomains for dopamine volume neurotransmission in primate prefrontal cortex. J. Neurosci. 24, 5292-5300. doi: 10.1523/JNEUROSCI.0195-04.2004
168. Pelayo-Teran, J. M., Suarez-Pinilla, P., Chadi, N., and Crespo-Facorro, B. (2012). Gene-environment interactions underlying the effect of cannabis in first episode psychosis. Curr. Pharm. Des. 18, 5024-5035. doi: 10.2174/138161212802884609
169. Penzes, P., Buonanno, A., Passafaro, M., Sala, C., and Sweet, R. A. (2013). Developmental vulnerability of synapses and circuits associated with neuropsychiatric disorders. J. Neurochem. 126, 165-182. doi: 10.1111/jnc.12261
170. Piton, A., Gauthier, J., Hamdan, F. F., Lafreniere, R. G., Yang, Y., Henrion, E., et al. (2011). Systematic resequencing of X-chromosome synaptic genes in autism spectrum disorder and schizophrenia. Mol. Psychiatry 16, 867-880. doi: 10.1038/mp.2010.54
171. Popp, J., Leucht, S., Heres, S., and Steimer, W. (2009). DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain. Pharmacogenomics J. 9, 71-77. doi: 10.1038/tpj.2008.5
172. Potkin, S. G., Basile, V. S., Jin, Y., Masellis, M., Badri, F., Keator, D., et al. (2003). D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol. Psychiatry 8, 109-113. doi: 10.1038/sj.mp.4001191
173. Purves-Tyson, T. D., Handelsman, D. J., Double, K. L., Owens, S. J., Bustamante, S., and Weickert, C. S. (2012). Testosterone regulation of sex steroid-related mRNAs and dopamine-related mRNAs in adolescent male rat substantia nigra. BMC Neurosci. 13:95. doi: 10.1186/1471-2202-13-95
174. Qiu, H. T., Meng, H. Q., Song, C., Xiu, M. H., Chen Da, C., Zhu, F. Y., et al. (2009). Association between monoamine oxidase (MAO)-A gene variants and schizophrenia in a Chinese population. Brain Res. 1287, 67-73. doi: 10.1016/j.brainres.2009.06.072
175. Quednow, B. B., Schmechtig, A., Ettinger, U., Petrovsky, N., Collier, D. A., Vollenweider, F. X., et al. (2009). Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase, but not on neuregulin-1 Arg38Gln genotype: a replication study. Biol. Psychiatry 66, 614-620. doi: 10.1016/j.biopsych.2009.05.007
176. Quednow, B. B., Wagner, M., Mossner, R., Maier, W., and Kuhn, K. U. (2010). Sensorimotor gating of schizophrenia patients depends on Catechol O-methyltransferase Val158Met polymorphism. Schizophr. Bull. 36, 341-346. doi: 10.1093/schbul/sbn088
177. Riecher-Rossler, A., Hafner, H., Dutsch-Strobel, A., Oster, M., Stumbaum, M., Van Gulick-Bailer, M., et al. (1994). Further evidence for a specific role of estradiol in schizophrenia? Biol. Psychiatry 36, 492-494. doi: 10.1016/0006-3223(94)90649-1
178. Riley, B., Mogudi-Carter, M., Jenkins, T., and Williamson, R. (1996). No evidence for linkage of chromosome 22 markers to schizophrenia in southern African Bantu-speaking families. Am. J. Med. Genet. 67, 515-522.
179. Risbrough, V., Ji, B., Hauger, R., and Zhou, X. (2014). Generation and characterization of humanized mice carrying COMT158 Met/Val alleles. Neuropsychopharmacology. doi: 10.1038/npp.2014.29. [Epub ahead of print].
180. Ritsner, M. S., Gibel, A., Shleifer, T., Boguslavsky, I., Zayed, A., Maayan, R., et al. (2010). Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J. Clin. Psychiatry 71, 1351-1362. doi: 10.4088/JCP.09m05031yel
181. Ritsner, M. S., and Strous, R. D. (2010). Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA. J. Psychiatr. Res. 44, 75-80. doi: 10.1016/j.jpsychires.2009.07.002
182. Rivett, A. J., Francis, A., and Roth, J. A. (1983). Distinct cellular localization of membrane-bound and soluble forms of catechol-O-methyltransferase in brain. J. Neurochem. 40, 215-219. doi: 10.1111/j.1471-4159.1983.tb12673.x
183. Rosier, J. P., Howes, O. D., Chaddock, C. A., Joyce, E. M., and McGuire, P. (2013). Neural and behavioral correlates of aberrant salience in individuals at risk for psychosis. Schizophr. Bull. 39, 1328-1336. doi: 10.1093/schbul/sbs147
184. Rowley, M., Bristow, L. J., and Hutson, P. H. (2001). Current and novel approaches to the drug treatment of schizophrenia. J. Med. Chem. 44, 477-501. doi: 10.1021/jm0002432
185. Rubin, L. H., Carter, C. S., Drogos, L., Pournajafi-Nazarloo, H., Sweeney, J. A., and Maki, P. M. (2010). Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr. Res. 124, 13-21. doi: 10.1016/j.schres.2010.09.014
186. Rybakowski, J. K., Borkowska, A., Czerski, P. M., Dmitrzak-Weglarz, M., Skibinska, M., Kapelski, P., et al. (2006). Performance on the Wisconsin Card Sorting Test in schizophrenia and genes of dopaminergic inactivation (COMT, DAT, NET). Psychiatry Res. 143, 13-19. doi: 10.1016/j.psychres.2005.10.008
187. Rybakowski, J. K., Borkowska, A., Czerski, P. M., and Hauser, J. (2002). Eye movement disturbances in schizophrenia and a polymorphism of catechol-O-methyltransferase gene. Psychiatric. Res. 113, 49-57. doi: 10.1016/S0165-1781(02)00245-7
188. Rybakowski, J. K., Borkowska, A., Czerski, P. M., Kapelski, P., Dmitrzak-Weglarz, M., and Hauser, J. (2005). An association study of dopamine receptors polymorphisms and the Wisconsin Card Sorting Test in schizophrenia. J. Neural Transm. 112, 1575-1582. doi: 10.1007/s00702-005-0292-6
189. Sabol, S. Z., Hu, S., and Hamer, D. (1998). A functional polymorphism in the monoamine oxidase A gene promoter. Hum. Genet. 103, 273-279. doi: 10.1007/s004390050816
190. Salminen, M., Lundstrom, K., Tilgmann, C., Savolainen, R., Kalkkinen, N., and Ulmanen, I. (1990). Molecular cloning and characterization of rat liver catechol-O-methyltransferase. Gene 93, 241-247. doi: 10.1016/0378-1119(90)90231-F
191. Sanchez, M. G., Bourque, M., Morissette, M., and Di Paolo, T. (2010). Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 16, e43-e71. doi: 10.1111/j.1755-5949.2010.00163.x
192. Sasaki, T., Hattori, M., Sakai, T., Kato, T., Kunugi, H., Hirose, T., et al. (1998). The monoamine oxidase-A gene and major psychosis in Japanese subjects. Biol. Psychiatry 44, 922-924. doi: 10.1016/S0006-3223(97)00522-2
193. Saura, J., Richards, J. G., and Mahy, N. (1994). Differential age-related changes of MAO-A and MAO-B in mouse brain and peripheral organs. Neurobiol. Aging 15, 399-408. doi: 10.1016/0197-4580(94)90071-X
194. Schenkel, L. S., Spaulding, W. D., Dilillo, D., and Silverstein, S. M. (2005). Histories of childhood maltreatment in schizophrenia: relationships with premorbid functioning, symptomatology, and cognitive deficits. Schizophr. Res. 76, 273-286. doi: 10.1016/j.schres.2005.03.003
195. Schott, B. H., Frischknecht, R., Debska-Vielhaber, G., John, N., Behnisch, G., Duzel, E., et al. (2010). Membrane-bound catechol-O-methyl transferase in cortical neurons and glial cells is intracellularly oriented. Front. Psychiatry 1:142. doi: 10.3389/fpsyt.2010.00142
196. Schott, B. H., Seidenbecher, C. I., Fenker, D. B., Lauer, C. J., Bunzeck, N., Bernstein, H. G., et al. (2006). The dopaminergic midbrain participates in human episodic memory formation: evidence from genetic imaging. J. Neurosci. 26, 1407-1417. doi: 10.1523/JNEUROSCI.3463-05.2006
197. Seeman, M. V. (1996). The role of estrogen in schizophrenia. J. Psychiatry Neurosci. 21, 123-127.
198. Seeman, P., and Lee, T. (1975). Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188, 1217-1219. doi: 10.1126/science.1145194
199. Semwal, P., Prasad, S., Bhatia, T., Deshpande, S. N., Wood, J., Nimgaonkar, V. L., et al. (2001). Family-based association studies of monoaminergic gene polymorphisms among North Indians with schizophrenia. Mol. Psychiatry 6, 220-224. doi: 10.1038/sj.mp.4000839
200. Sesack, S. R., Hawrylak, V. A., Matus, C., Guido, M. A., and Levey, A. I. (1998). Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J. Neurosci. 18, 2697-2708.
201. Shifman, S., Bronstein, M., Sternfeld, M., Pisanté-Shalom, A., Lev-Lehman, E., Weizman, A., et al. (2002). A highly significant association between a COMT haplotype and schizophrenia. Am. J. Hum. Genet. 71, 1296-1302. doi: 10.1086/344514
202. Shih, J. C., and Thompson, R. F. (1999). Monoamine oxidase in neuropsychiatry and behavior. Am. J. Hum. Genet. 65, 593-598. doi: 10.1086/302562
203. Singh, J. P., Volavka, J., Czobor, P., and Van Dorn, R. A. (2012). A meta-analysis of the Val158Met COMT polymorphism and violent behavior in schizophrenia. PLoS ONE 7:e43423. doi: 10.1371/journal.pone.0043423
204. Sjoberg, R. L., Ducci, F., Barr, C. S., Newman, T. K., Dell'osso, L., Virkkunen, M., et al. (2008). A non-additive interaction of a functional MAO-A VNTR and testosterone predicts antisocial behavior. Neuropsychopharmacology 33, 425-430. doi: 10.1038/sj.npp.1301417
205. Smieskova, R., Marmy, J., Schmidt, A., Bendfeldt, K., Riecher-R?ssler, A., Walter, M., et al. (2013). Do subjects at clinical high risk for psychosis differ from those with a genetic high risk?-A systematic review of structural and functional brain abnormalities. Curr. Med. Chem. 20, 467-481.
206. Smolka, M. N., Schumann, G., Wrase, J., Grusser, S. M., Flor, H., Mann, K., et al. (2005). Catechol-O-methyltransferase val158met genotype affects processing of emotional stimuli in the amygdala and prefrontal cortex. J. Neurosci. 25, 836-842. doi: 10.1523/JNEUROSCI.1792-04.2005
207. Snell, L. D., Glanz, J., Tabakoff, B., State, W. I. S. O., Trait Markers Ofalcohol, U., and Dependence, I. (2002). Relationships between effects of smoking, gender, and alcohol dependence on platelet monoamine oxidase-B: activity, affinity labeling, and protein measurements. Alcohol. Clin. Exp. Res. 26, 1105-1113. doi: 10.1111/j.1530-0277.2002.tb02645.x
208. Sobell, J. L., Lind, T. J., Hebrink, D. D., Heston, L. L., and Sommer, S. S. (1997). Screening the monoamine oxidase B gene in 100 male patients with schizophrenia: a cluster of polymorphisms in African-Americans but lack of functionally significant sequence changes. Am. J. Med. Genet. 74, 44-49.
209. Soyka, M. (2011). Neurobiology of aggression and violence in schizophrenia. Schizophr. Bull. 37, 913-920. doi: 10.1093/schbul/sbr103
210. Spear, L. P. (2000). The adolescent brain and age-related behavioral manifestations. Neurosci. Biobehav. Rev. 24, 417-463. doi: 10.1016/S0149-7634(00)00014-2
211. Stefanis, N. C., Henquet, C., Avramopoulos, D., Smyrnis, N., Evdokimidis, I., Myin-Germeys, I., et al. (2007). COMT Val158Met moderation of stress-induced psychosis. Psychol. Med. 37, 1651-1656. doi: 10.1017/S0033291707001080
212. Stokes, P. R., Shotbolt, P., Mehta, M. A., Turkheimer, E., Benecke, A., Copeland, C., et al. (2013). Nature or nurture? Determining the heritability of human striatal dopamine function: an [18F]-DOPA PET study. Neuropsychopharmacology 38, 485-491. doi: 10.1038/npp.2012.207
213. Strous, R. D., Bark, N., Parsia, S. S., Volavka, J., and Lachman, H. M. (1997). Analysis of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association with aggressive and antisocial behavior. Psychiatry Res. 69, 71-77. doi: 10.1016/S0165-1781(96)03111-3
214. Strous, R. D., Lapidus, R., Viglin, D., Kotler, M., and Lachman, H. M. (2006). Analysis of an association between the COMT polymorphism and clinical symptomatology in schizophrenia. Neurosci. Lett. 393, 170-173. doi: 10.1016/j.neulet.2005.09.067
215. Sumner, B. E., and Fink, G. (1993). Effects of acute estradiol on 5-hydroxytryptamine and dopamine receptor subtype mRNA expression in female rat brain. Mol. Cell. Neurosci. 4, 83-92. doi: 10.1006/mcne.1993.1010
216. Sun, J., Jayathilake, K., Zhao, Z., and Meltzer, H. Y. (2012a). Investigating association of four gene regions (GABRB3, MAOB, PAH, and SLC6A4) with five symptoms in schizophrenia. Psychiatry Res. 198, 202-206. doi: 10.1016/j.psychres.2011.12.035
217. Sun, Y., Zhang, J., Yuan, Y., Yu, X., Shen, Y., and Xu, Q. (2012b). Study of a possible role of the monoamine oxidase A (MAOA) gene in paranoid schizophrenia among a Chinese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 159B, 104-111. doi: 10.1002/ajmg.b.32009
218. Sweet, R. A., Devlin, B., Pollock, B. G., Sukonick, D. L., Kastango, K. B., Bacanu, S. A., et al. (2005). Catechol-O-methyltransferase haplotypes are associated with psychosis in Alzheimer disease. Mol. Psychiatry 10, 1026-1036. doi: 10.1038/sj.mp.4001709
219. Syagailo, Y. V., Stober, G., Grassle, M., Reimer, E., Knapp, M., Jungkunz, G., et al. (2001). Association analysis of the functional monoamine oxidase A gene promoter polymorphism in psychiatric disorders. Am. J. Med. Genet. 105, 168-171. doi: 10.1002/ajmg.1193
220. Tan, H. Y., Callicott, J. H., and Weinberger, D. R. (2007). Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb. Cortex 17(Suppl. 1), i171-i181. doi: 10.1093/cercor/bhm069
221. Teicher, M. H., Andersen, S. L., and Hostetter, J. C. Jr. (1995). Evidence for dopamine receptor pruning between adolescence and adulthood in striatum but not nucleus accumbens. Brain Res. Dev. Brain Res. 89, 167-172. doi: 10.1016/0165-3806(95)00109-Q
222. Tenhunen, J., Salminen, M., Jalanko, A., Ukkonen, S., and Ulmanen, I. (1993). Structure of the rat catechol-O-methyltransferase gene: separate promoters are used to produce mRNAs for soluble and membrane-bound forms of the enzyme. DNA Cell Biol. 12, 253-263. doi: 10.1089/dna.1993.12.253
223. Thiblin, I., Finn, A., Ross, S. B., and Stenfors, C. (1999). Increased dopaminergic and 5-hydroxytryptaminergic activities in male rat brain following long-term treatment with anabolic androgenic steroids. Br. J. Pharmacol. 126, 1301-1306. doi: 10.1038/sj.bjp.0702412
224. Tosato, S., Bonetto, C., Di Forti, M., Collier, D., Cristofalo, D., Bertani, M., et al. (2011). Effect of COMT genotype on aggressive behaviour in a community cohort of schizophrenic patients. Neurosci. Lett. 495, 17-21. doi: 10.1016/j.neulet.2011.03.018
225. Tsai, G., and Coyle, J. T. (2002). Glutamergic mechanisms in schizophrenia. Annu. Rev. Pharmacol. Toxicol. 42, 165-179. doi: 10.1146/annurev.pharmtox.42.082701.160735
226. Tunbridge, E. M., Harrison, P. J., and Weinberger, D. R. (2006). Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol. Psychiatry 60, 141-151. doi: 10.1016/j.biopsych.2005.10.024
227. Ulmanen, I., Peranen, J., Tenhunen, J., Tilgmann, C., Karhunen, T., Panula, P., et al. (1997). Expression and intracellular localization of catechol O-methyltransferase in transfected mammalian cells. Eur. J. Biochem. 243, 452-459. doi: 10.1111/j.1432-1033.1997.0452a.x
228. Vaccari, A., Caviglia, A., Sparatore, A., and Biassoni, R. (1981). Gonadal influences on the sexual differentiation of monoamine oxidase type A and B activities in the rat brain. J. Neurochem. 37, 640-648. doi: 10.1111/j.1471-4159.1982.tb12535.x
229. Van Os, J., Kenis, G., and Rutten, B.P. (2010). The environment and schizophrenia. Nature 468, 203-212. doi: 10.1038/nature09563
230. Van Os, J., and Murray, R. (2008). Introduction. Schizophr. Bull. 34, 1064-1065. doi: 10.1093/schbul/sbn116
231. Van Os, J., and Rutten, B. P. (2009). Gene-environment-wide interaction studies in psychiatry. Am. J. Psychiatry166, 964-966. doi: 10.1176/appi.ajp.2008.09060904
232. Van Os, J., Rutten, B. P., and Poulton, R. (2008). Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr. Bull. 34, 1066-1082. doi: 10.1093/schbul/sbn117
233. Voisey, J., Swagell, C. D., Hughes, I. P., Lawford, B. R., Young, R. M., and Morris, C. P. (2012). HapMap tag-SNP analysis confirms a role for COMT in schizophrenia risk and reveals a novel association. Eur. Psychiatry 27, 372-376. doi: 10.1016/j.eurpsy.2010.08.004
234. Wahlstrom, D., White, T., Hooper, C. J., Vrshek-Schallhorn, S., Oetting, W. S., Brott, M. J., et al. (2007). Variations in the catechol O-methyltransferase polymorphism and prefrontally guided behaviors in adolescents. Biol. Psychiatry 61, 626-632. doi: 10.1016/j.biopsych.2006.05.045
235. Wang, S., Li, W., Zhao, J., Zhang, H., Yang, Y., Wang, X., et al. (2013). Association of estrogen receptor alpha gene polymorphism with age at onset, general psychopathology symptoms, and therapeutic effect of schizophrenia. Behav. Brain Funct. 9, 12. doi: 10.1186/1744-9081-9-12
236. Wei, J., and Hammings, G. (1998). Allelic association between dinucleotide repeats at the monoamine oxidase loci and schizophrenia. Eur. Psychiatry 13, 407-410. doi: 10.1016/S0924-9338(99)80687-7
237. Wei, J., and Hemmings, G. P. (1999). Lack of evidence for association between the COMT locus and schizophrenia. Psychiatr. Genet. 9, 183-186. doi: 10.1097/00041444-199912000-00003
238. Wei, J., Ramchand, C. N., Clark, A. E., and Hemmings, G. P. (1996). A study of enzymes involved in catecholamine metabolism in parents of patients with schizophrenia. Schizophr. Res. 19, 27-32. doi: 10.1016/0920-9964(95)00044-5
239. Wei, Y. L., Li, C. X., Li, S. B., Liu, Y., and Hu, L. (2011). Association study of monoamine oxidase A/B genes and schizophrenia in Han Chinese. Behav. Brain Funct. 7, 42. doi: 10.1186/1744-9081-7-42
240. Weickert, C. S., Miranda-Angulo, A. L., Wong, J., Perlman, W. R., Ward, S. E., Radhakrishna, V., et al. (2008). Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia. Hum. Mol. Genet. 17, 2293-2309. doi: 10.1093/hmg/ddn130
241. Weinberger, D. R. (1987). Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 44, 660-669. doi: 10.1001/archpsyc.1987.01800190080012
242. Weinberger, D. R. (2002). Schizophrenia, the prefrontal cortex, and a mechanism of genetic susceptibility. Eur Psychiatry 17(Suppl. 4), 355s-362s. doi: 10.1016/S0924-9338(03)00080-4
243. Weinberger, D. R., Egan, M. F., Bertolino, A., Callicott, J. H., Mattay, V. S., Lipska, B. K., et al. (2001). Prefrontal neurons and the genetics of schizophrenia. Biol. Psychiatry 50, 825-844. doi: 10.1016/S0006-3223(01)01252-5
244. Westlund, K. N., Denney, R. M., Rose, R. M., and Abell, C. W. (1988). Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25, 439-456. doi: 10.1016/0306-4522(88)90250-3
245. Williams, H. J., Owen, M. J., and O'Donovan, M. C. (2007). Is COMT a susceptibility gene for schizophrenia?Schizophr. Bull. 33, 635-641. doi: 10.1093/schbul/sbm019
246. Winterer, G., Egan, M. F., Kolachana, B. S., Goldberg, T. E., Coppola, R., and Weinberger, D. R. (2006). Prefrontal electrophysiologic "noise" and catechol-O-methyltransferase genotype in schizophrenia. Biol. Psychiatry 60, 578-584. doi: 10.1016/j.biopsych.2006.03.023
247. Winton-Brown, T. T., Fusar-Poli, P., Ungless, M. A., and Howes, O. D. (2014). Dopaminergic basis of salience dysregulation in psychosis. Trends Neurosci. 37, 85-94. doi: 10.1016/j.tins.2013.11.003
248. Xie, T., Ho, S. L., and Ramsden, D. (1999). Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol. Pharmacol. 56, 31-38.
249. Yasui-Furukori, N., Saito, M., Tsuchimine, S., Nakagami, T., Sato, Y., Sugawara, N., et al. (2008). Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 1491-1495. doi: 10.1016/j.pnpbp.2008.05.006
250. Yavich, L., Forsberg, M. M., Karayiorgou, M., Gogos, J. A., and Männistö, P. T. (2007). Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. J. Neurosci. 27, 10196-10209. doi: 10.1523/JNEUROSCI.0665-07.2007
251. Zai, C. C., Tiwari, A. K., Müller, D. J., De Luca, V., Shinkai, T., Shaikh, S., et al. (2010). The catechol-O-methyl-transferase gene in tardive dyskinesia. World J. Biol. Psychiatry 11, 803-812. doi: 10.3109/15622975.2010.486043
252. Zhao, Q. Z., Liu, B. C., Zhang, J., Wang, L., Li, X. W., Wang, Y., et al. (2012). Association between a COMT polymorphism and clinical response to risperidone treatment: a pharmacogenetic study. Psychiatr. Genet. 22, 298-299. doi: 10.1097/YPG.0b013e328358629a
253. Zhu, B. T., and Conney, A. H. (1998). Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19, 1-27. doi: 10.1093/carcin/19.1.1